Akebia Therapeutics, Inc. (AKBA) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	8-K	10-Q	8-K	10-Q	10-Q	10-K	10-Q	10-Q
Revenues:
Total revenues				296.8	223.0	213.6	210.7	221.9
Total revenues growth				33.8%	-14.0%	-27.7%	-31.6%	-34.8%
Cost of goods sold:
Product				80.2	114.1	117.4	132.0	149.3
Amortization of intangibles				36.0	36.0	36.0	34.2	31.3
Total cost of goods sold				116.2	150.1	153.4	166.3	180.7

Operating expenses:
Research and development				139.9	151.1	147.9	155.9	162.3
Selling, general and administrative				168.3	177.2	174.2	169.6	163.5
License expense				3.5	3.5	3.5	3.4	3.3
Restructuring				14.5
Total operating expenses				326.2	331.7	325.5	406.8	406.9
Operating loss				-145.6	-258.9	-265.3	-284.6	-287.8
Operating margin				-49.1%	-116.1%	-124.2%	-135.1%	-129.7%

Other income (expense):
Interest expense				-20.3	-20.2	-19.9	-17.2	-14.4
Other income				2.5	3.4	2.4	2.6	2.6
Net loss, basic				-33.1	-145.5			-83.0
Net loss, diluted				-33.1	-145.5			-83.0

Net loss per share - basic (in dollars per share)				($0.93)	($1.60)	($1.70)	($1.89)	($1.97)
Net loss per share - diluted (in dollars per share)				($0.94)	($1.60)	($1.70)	($1.89)	($1.97)

Weighted-average number of common shares - basic (in shares)				175.7	170.2	163.7	156.8	149.2
Weighted-average number of common shares - diluted (in shares)				177.4	170.2	163.7	156.8	149.2

Comprehensive loss:
Net loss				-163.4	-275.7	-282.8	-299.2	-299.6
Total comprehensive loss				-163.4	-275.7	-282.8	-299.2	-299.6